… Institute of Canada Clinical Trials Group conducted a phase III randomized trial, named
BR.21, in which erlotinib was compared with placebo in stage III/IV NSCLC patients who had …

… The activity of erlotinib compares favorably with that of docetaxel in less heavily pretreated
patients in phase II 25 and phase III studies. Erlotinib has a favorable safety profile, with rash …

… -molecule tyrosine kinase inhibitor erlotinib may be considered … consisting of the oral agents
erlotinib and sorafenib, an … activity than erlotinib alone to merit a subsequent phase III trial. …

… In a clinical positron emission tomography study using C 11 erlotinib, regression of both
BM and the primary lung tumor in a patient harboring an EGFR mutation was reported [19]. A …

… explored, but no current phase III data show superiority of an … An association between
estrogens and lung cancer risk first … when an increase in lung cancer mortality was observed in …

… erlotinib clinical trials—4 phase 2 trials and 1 phase 3 trial in which erlotinib was used as a
single agent and 2 large phase 3 trials in which erlotinib was administered concomitantly with …

Background: BR.21 is a double-blind, placebo-controlled trial of second-/third-line erlotinib
in stage IIIB/IV non-small cell lung cancer patients. Predictive and prognostic analyses of …

… If 50% of patients had EGFR + tumors by IHC (based on a phase III erlotinib trial in patients
with advanced NSCLC after failure of at least one prior chemotherapy regimen, wherein 47% …

… EMPHASIS-lung was a randomized phase III multicenter trial exploring the differential
effect of second-line erlotinib versus docetaxel on progression-free survival (PFS) in VeriStrat …

… We found that continuing erlotinib with chemotherapy improves the response rate and is
therefore a reasonable treatment option for patients with EGFR-mutant lung cancer acquired …